PRNAF — ALTERITY THERAPEUTICS LTD

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1131343 · Australia
Last close
$0.25
Market Cap
$54.63M
52W High
$0.55
52W Low
$0.00
ADV30
83
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 — — — — 46,019,461 37,317,962 3,294,499
Dec 2025 — — — — 56,918,905 49,200,547 2,650,906
Jun 2025 — — — — 46,026,360 33,158,642 3,623,274
Dec 2024 — — — — 10,546,933 4,536,559 2,760,926

Balance + Analyst (yfinance extras)

Retained Earnings
$-234,379,461
Inventory
—
Receivables
$6,842,493
ST Investments
$7,500,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$3,610,016
EBITDA
$-25,090,684
Free Cash Flow
$-14,740,514
Enterprise Value
$50,275,672
Total Cash
$37,317,960
Total Debt
$193,465
Shares Out
218,500,420
Trailing EPS
$-0.08
Book Value
$0.14
ROE
-55.0%
ROA
-34.1%
Div Yield
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Jun 2026 0 -25,094,229 -23,400,949 46,019,461 3,294,499 42,724,962 —
Jun 2025 0 -12,461,203 -12,147,828 46,026,360 3,623,274 42,403,086 -11,451,248
Jun 2024 0 -19,616,621 -19,123,464 19,223,743 5,425,686 13,798,057 -12,605,824
Jun 2023 0 -14,653,292 -13,806,515 27,317,636 4,504,727 22,812,909 -20,035,837
Jun 2022 — — — — — — -12,337,274

Peers — same industry

TickerNameMarket CapLastDaily %
GANX Gain Therapeutics, Inc. $54.55M $1.25 —
XLO Xilio Therapeutics, Inc. $54.81M $8.33 —
PLRX PLIANT THERAPEUTICS, INC. $55.65M $0.90 —
TLPH TALPHERA, INC. $56.06M $1.08 —
CNTB Connect Biopharma Holdings Ltd $56.66M $0.90 —

News headlines (Yahoo Finance, 1h cache)

Ather Energy (NSEI:ATHERENERG) Stock Sees Modest Fair Value Lift On Stronger Growth Assumptions
2026-10-09 17:19 · Yahoo
Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference
2026-10-09 11:05 · Yahoo
Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders
2026-10-05 11:05 · Yahoo
Alterity Therapeutics CEO speaks with Proactive at the ASX SMIDcaps Conference
2026-09-23 09:07 · Yahoo
Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026
2026-09-03 11:05 · Yahoo
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
2026-08-12 11:05 · Yahoo
Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference
2026-08-06 11:25 · Yahoo
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
2026-07-30 11:25 · Yahoo
Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
2026-07-21 11:25 · Yahoo
Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
2026-07-07 11:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.